Impact BioMedical Inc. IBO
Set alert
At close
Pre-market · Nov 2, 4:53 AM ET
- YTD
- -40.53%
- 1 year
- -42.94%
- Open
- 3.52
- Prev close
- 3.87
- Mkt cap
- 32.47M
- Vol
- 15.29K
- Avg vol
- 15.90K
- EPS
- 11.11
- P/E
- 0.34
- Div yield
- 0.00%
More statistics
- Low
- 3.68
- High
- 4.00
- Forward P/E
- 0.00
- Beta
- 0.00
- Short ratio
- 0.06
- Inst. own
- 1.42%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 2.23
- 200-d avg
- 2.17
- 1y target
- 0.00
Key statistics
- Market cap
- 16.57M
- Enterprise value
- 21.75M
- Trailing P/E
- 14.40
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.53
- EPS (TTM)
- 0.10
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -1.33M
- Total cash
- 2.67M
- Total debt
- 8.01M
- Return on equity
- 3.45%
- Shares outstanding
- 11.50M
- Short % of float
- 0.00%
- 50-day average
- 2.23
- 200-day average
- 2.17
Analyst view
Consensus: none
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
About Impact BioMedical Inc.
Impact BioMedical Inc. focused on discovery, development, and commercialization of products and technologies to address unmet needs in human healthcare and wellness for specialty biopharmaceuticals, antivirals, antimicrobials, consumer healthcare, and wellness products in the United States. The company provides Linebacker, a platform of small molecule electrophilically enhanced polyphenol compounds with application in oncology, inflammatory disorders, and neurology; and Laetose technology that is derived from a unique combination of sugar and inositol, which can inhibit the inflammatory and metabolic response of sugar alone. It also develops functional fragrance formulation, a suite of functional fragrances containing specialized botanical ingredients with application as an antimicrobial, and as an additive in insect repellents, detergents, lotions, shampoo, fabrics, and other substances. In addition, the company develops Equivir/Equivir G technology, a novel blend of polyphenols, which have demonstrated antiviral effects for use in as health supplements and medications. Impact BioMedical Inc. was incorporated in 2018 and is based in Houston, Texas.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- impactbiomedinc.com
News
Your note
Sign in to keep a note on IBO — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Ferguson Wellman Capital Management, Inc. | 0.00% | 36,364 | 52.36K | Sep 29, 2024 |
| HRT Financial LP | 0.00% | 12,502 | 18.00K | Sep 29, 2024 |
| Wells Fargo & Company | 0.00% | 29 | 41 | Sep 29, 2024 |
| Jane Street Group, LLC | 0.00% | 13,361 | 19.24K | Sep 29, 2024 |
| Bank of America Corporation | 0.00% | 2,596 | 3.74K | Sep 29, 2024 |
| Barclays Plc | 0.00% | 1,120 | 1.61K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Balanced Index Fund | 0.00% | 154,000 | 221.76K | Sep 29, 2024 |
| Vanguard Total Stock Market Index Fund | 0.00% | 5,171,052 | 7.45M | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.00% | 26,770 | 38.55K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.00% | 5,820 | 8.38K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.00% | 2,449 | 3.53K | Oct 30, 2024 |